Abstract
Summary
Middle East and Africa antiviral drugs market is expected to reach USD 2,225.82 million by 2030 from USD 1,771.23 million in 2022, growing with a CAGR of 2.9% during the forecast period from 2023 to 2030.
Market Segmentation:
Middle East and Africa Antiviral Drugs Market, By Indication (Influenza, Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Respiratory Syncytial Virus (RSV), Herpes Simplex Virus, Human Cytomegalovirus (HCMV), Varicella-Zoster Virus (VZV), Hepatitis B Virus (HBV), Coronavirus Infection, and Others), Patient Type (Child, Adult, and Geriatric), Products (Oral, Topical, and Parenteral), Drug Type (Generic and Branded), End User (Hospitals, Clinics, Home Healthcare, Specialty Centers, Ambulatory Centers, and Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy) Country (South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Kuwait, and Rest of Middle East and Africa) Industry Trends and Forecast to 2030.
Overview of Middle East and Africa Antiviral Drugs Market Dynamics :
Driver
• Rising prevalence of viral infections
Restrain
• High cost of antiviral drugs
Opportunity
• Increasing collaboration and partnership among key players
Market Players:
Some of the key market players operating in the Middle East and Africa antiviral drugs market are listed below:
• Gilead Sciences, Inc.
• F. Hoffmann-La Roche Ltd
• GLAXOSMITHKLINE PLC
• Abbvie
• Merck & Co., Inc.
• Johnson & Johnson Services, Inc.
• Bristol-Myers Squibb Company
• Cipla Inc.
• Aurobindo Pharma
• Dr. Reddy’s Laboratories Ltd.
• Zydus Pharmaceuticals, Inc.
• Mylan Pharmaceuticals ULC
• Teva Pharmaceuticals USA, Inc.
• EMERGENT
• Sun Pharmaceutical Industries Ltd.
• Avet Pharmaceuticals Inc.
• Pfizer Inc.
• SIGA Technologies
• NAVINTA LLC.
• Macleods Pharmaceuticals Ltd.
• BioCryst Pharmaceuticals, Inc
• Hetero
Table of Contents
1 INTRODUCTION 119
1.1 OBJECTIVES OF THE STUDY 119
1.2 MARKET DEFINITION 119
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET 119
1.4 LIMITATIONS 121
1.5 MARKETS COVERED 121
2 MARKET SEGMENTATION 127
2.1 MARKETS COVERED 127
2.2 GEOGRAPHICAL SCOPE 128
2.3 YEARS CONSIDERED FOR THE STUDY 129
2.4 CURRENCY AND PRICING 129
2.5 DBMR TRIPOD DATA VALIDATION MODEL 130
2.6 MULTIVARIATE MODELLING 133
2.7 PRODUCT TYPE LIFELINE CURVE 133
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 134
2.9 DBMR MARKET POSITION GRID 135
2.10 MARKET TESTING TYPE COVERAGE GRID 136
2.11 VENDOR SHARE ANALYSIS 137
2.12 SECONDARY SOURCES 138
2.13 ASSUMPTIONS 138
3 EXECUTIVE SUMMARY 139
4 PREMIUM INSIGHTS 142
4.1 PORTER’S FIVE FORCES 143
4.2 PESTEL ANALYSIS 144
5 EPIDEMIOLOGY 145
6 PIPELINE ANALYSIS FOR MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET 146
7 REGULATORY FRAMEWORK 147
8 MARKET OVERVIEW 149
8.1 DRIVERS 151
8.1.1 RISING PREVALENCE OF VIRAL INFECTIONS 151
8.1.2 ADVANCEMENTS IN NEW ANTIVIRAL DRUG DEVELOPMENT 151
8.1.3 GROWING DEMAND FOR COMBINATION THERAPIES 153
8.1.4 INCREASING GOVERNMENT FUNDING AND R&D ACTIVITIES 153
8.2 RESTRAINS 154
8.2.1 HIGH COST OF ANTIVIRAL DRUGS 154
8.2.2 EMERGENCE OF DRUG-RESISTANT STRAINS OF VIRUSES 154
8.3 OPPORTUNITIES 155
8.3.1 INCREASING COLLABORATION AND PARTNERSHIP AMONG KEY PLAYERS 155
8.3.2 RISING NOVEL DRUG DELIVERY SYSTEMS 155
8.3.3 DEVELOPMENT OF PERSONALIZED MEDICINES 156
8.4 CHALLENGES 157
8.4.1 PATENT EXPIRATION OF ANTIVIRAL DRUGS 157
8.4.2 DEMAND FOR ALTERNATIVE MEDICINES 158
9 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY INDICATION 159
9.1 OVERVIEW 160
9.2 INFLUENZA 163
9.2.1 NEURAMINIDASE INHIBITORS 164
- 9.2.1.1 OSELTAMIVIR 164
- 9.2.1.2 ZANAMIVIR 164
- 9.2.1.3 PERAMIVIR 164
- 9.2.1.4 LANINAMIVIR 164
9.2.2 M2 INHIBITORS 165
- 9.2.2.1 RIMANTADINE 165
- 9.2.2.2 OTHERS 165
9.2.3 RNA POLYMERASE INHIBITORS 165
- 9.2.3.1 FAVIPIRAVIR 165
- 9.2.3.2 BALOXAVIR MARBOXIL 165
9.3 HUMAN IMMUNODEFICIENCY VIRUS (HIV) 166
9.3.1 REVERSE TRANSCRIPTASE INHIBITORS 167
- 9.3.1.1 NUCLEOSIDE (NRTIS) 167
- 9.3.1.1.1 LAMIVUDINE 168
- 9.3.1.1.2 ABACAVIR 168
- 9.3.1.1.3 DIDANOSINE 168
- 9.3.1.1.4 OTHERS 168
- 9.3.1.2 NONNUCLEOSIDE (NNRTIS) 168
- 9.3.1.2.1 EFAVIRENZ 168
- 9.3.1.2.2 NEVIRAPINE 168
- 9.3.1.2.3 DELAVIRDINE 168
- 9.3.1.2.4 OTHERS 169
- 9.3.1.3 INTEGRASE 169
- 9.3.1.3.1 DOLUTEGRAVIR 169
- 9.3.1.3.2 ELVITEGRAVIR 169
- 9.3.1.3.3 RALTEGRAVIR 169
- 9.3.1.3.4 BICTEGRAVIR 169
- 9.3.1.4 NUCLEOTIDE 169
- 9.3.1.4.1 TENOFOVIR 170
- 9.3.1.4.2 OTHERS 170
- 9.3.1.5 INTERFERONS 170
- 9.3.1.5.1 ALPHA 170
- 9.3.1.5.2 BETA 170
- 9.3.1.5.3 GAMMA 171
- 9.3.1.6 GP41 171
- 9.3.1.6.1 ENFUVIRTIDE 171
- 9.3.1.6.2 OTHERS 171
- 9.3.1.1 NUCLEOSIDE (NRTIS) 167
9.3.2 PROTEASE 172
- 9.3.2.1 ATAZANAVIR 172
- 9.3.2.2 DARUNAVIR 172
- 9.3.2.3 LOPINAVIR 172
- 9.3.2.4 RITONAVIR 172
- 9.3.2.5 SAQUINAVIR 172
- 9.3.2.6 INDINAVIR 172
- 9.3.2.7 NELFINAVIR 173
- 9.3.2.8 TIPRANAVIR 173
- 9.3.2.9 AMPRENAVIR 173
9.4 HEPATITIS C VIRUS 173
9.4.1 NS5B POLYMERASE 174
- 9.4.1.1 SOFOSBUVIR 174
- 9.4.1.2 DASABUVIR 174
9.4.2 NS3/4A PROTEASE 175
- 9.4.2.1 DANOPREVIR 175
- 9.4.2.2 GLECAPREVIR 175
- 9.4.2.3 GRAZOPREVIR 175
- 9.4.2.4 PARITAPREVIR 175
- 9.4.2.5 SIMEPREVIR 175
9.4.3 NS5A PHOSPHOPROTEIN 176
- 9.4.3.1 LEDIPASVIR 176
- 9.4.3.2 VELPATASVIR 176
- 9.4.3.3 OMBITASVIR 176
- 9.4.3.4 ELBASVIR 176
- 9.4.3.5 DACLATASVIR 176
- 9.4.3.6 PIBRENTASVIR 176
9.4.4 NEURAMINIDASE 177
- 9.4.4.1 OSELTAMIVIR 177
- 9.4.4.2 ZANAMIVIR 177
- 9.4.4.3 PERAMIVIR 177
- 9.4.4.4 LANINAMIVIR 177
9.4.5 RNA POLYMERASE 177
- 9.4.5.1 BALOXAVIR MARBOXIL 178
- 9.4.5.2 FAVIPIRAVIR 178
9.4.6 MATRIX PROTEIN 2 178
- 9.4.6.1 RIMATIDINE 178
- 9.4.6.2 FAVIPIRAVIR 178
9.5 HERPES SIMPLEX VIRUS 179
9.5.1 DNA POLYMERASE UL30 180
- 9.5.1.1 ACICLOVIR 180
- 9.5.1.2 FAMCICLOVIR 180
- 9.5.1.3 VALACICLOVIR 180
- 9.5.1.4 PENCICLOVIR TRIFLURIDINE 180
- 9.5.1.5 BRIVUDINE 180
- 9.5.1.6 FOSCARNET 180
- 9.5.1.7 IDOXURIDINE 181
9.5.2 ENVELOPE PROTEINS 181
- 9.5.2.1 DOCOSANOL 181
- 9.5.2.2 OTHERS 181
9.6 HUMAN CYTOMEGALOVIRUS (HCMV) 181
9.6.1 GANCICLOVIR 182
9.6.2 VALGANCICLOVIR 182
9.6.3 CIDOFOVIR 182
9.6.4 FOSCARNET 182
9.6.5 FOMIVIRSEN 182
9.7 VARICELLA-ZOSTER VIRUS (VZV) 183
9.7.1 VALACICLOVIR 184
9.7.2 FAMCICLOVIR 184
9.7.3 ACICLOVIR 184
9.7.4 VIDARABINE 184
9.7.5 BRIVUDINE 184
9.8 HEPATITIS B VIRUS 184
9.8.1 ENTECAVIR 185
9.8.2 TENOFOVIR 185
9.8.3 TELBIVUDINE 185
9.8.4 TENOFOVIR ALAFENAMIDE 186
9.8.5 OTHERS 186
9.9 RESPIRATORY SYNCYTIAL VIRUS 186
9.9.1 RNA POLYMERASE 187
- 9.9.1.1 RIBAVIRIN 187
- 9.9.1.2 OTHERS 187
9.9.2 FUSION GLYCOPROTEIN 187
- 9.9.2.1 PALIVIZUMAB 188
- 9.9.2.2 OTHERS 188
9.10 CORONAVIRUS INFECTION 188
9.11 OTHERS 189
10 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY PATIENT TYPE 190
10.1 OVERVIEW 191
10.2 GERIATRIC 194
10.2.1 MALE 194
10.2.2 FEMALE 194
10.3 CHILD 195
10.3.1 MALE 195
10.3.2 FEMALE 196
10.4 ADULT 196
10.4.1 MALE 197
10.4.2 FEMALE 197
11 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY PRODUCTS 198
11.1 OVERVIEW 199
11.2 ORAL 202
11.2.1 SOLID 203
- 11.2.1.1 TABLETS 203
- 11.2.1.2 CAPSULES 203
- 11.2.1.3 OTHERS 203
11.2.2 SEMISOLID 203
- 11.2.2.1 GELS 204
- 11.2.2.2 EMULSIONS 204
- 11.2.2.3 ELIXIRS 204
- 11.2.2.4 OTHERS 204
11.2.3 LIQUID 204
- 11.2.3.1 SOLUTIONS 204
- 11.2.3.2 SYRUPS 204
- 11.2.3.3 OTHERS 204
11.3 TOPICAL 205
11.3.1 SEMI-SOLID 206
- 11.3.1.1 CREAM 206
- 11.3.1.2 OINTMENT 206
- 11.3.1.3 GELS 206
- 11.3.1.4 OTHERS 206
11.3.2 LIQUID 206
- 11.3.2.1 SOLUTIONS 207
- 11.3.2.2 SUSPENSIONS 207
11.3.3 SOLID 207
- 11.3.3.1 POWDERS 207
- 11.3.3.2 SUPPOSITORIES 207
- 11.3.3.3 ENEMA 207
- 11.3.3.4 OTHERS 207
11.4 PARENTERAL 208
11.4.1 CONVENTIONAL DRUG DELIVERY FORMUALTIONS 209
- 11.4.1.1 SOLUTIONS 209
- 11.4.1.2 RECONSTITUTED/LYOPHILIZED 209
- 11.4.1.3 SUSPENSIONS 209
- 11.4.1.4 EMULSIONS 209
- 11.4.1.5 OTHERS 209
11.4.2 NOVEL DRUG DELIVERY FORMULATIONS 210
11.4.3 COLLOIDAL DISPERSIONS 210
11.4.4 LONG ACTING INJECTION FORMULATION 210
12 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY DRUG TYPE 211
12.1 OVERVIEW 212
12.2 GENERIC 215
12.3 BRANDED 215
13 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY END USER 216
13.1 OVERVIEW 217
13.2 HOSPITAL 220
13.3 SPECIALTY CENTERS 220
13.4 AMBULATORY CENTRES 221
13.5 CLINICS 221
13.6 HOME HEALTHCARE 221
13.7 OTHERS 222
14 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY DISTRIBUTION CHANNEL 223
14.1 OVERVIEW 224
14.2 HOSPITAL PHARMACY 227
14.3 RETAIL PHARMACY 227
14.4 ONLINE PHARMACY 228
15 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET, BY REGION 229
15.1 MIDDLE EAST AND AFRICA 230
15.1.1 SOUTH AFRICA 249
15.1.2 SAUDI ARABIA 263
15.1.3 UAE 277
15.1.4 EGYPT 291
15.1.5 KUWAIT 305
15.1.6 ISRAEL 319
15.1.7 REST OF MIDDLE EAST AND AFRICA 333
16 MIDDLE EAST AND AFRICA ANTIVIRAL DRUGS MARKET: COMPANY LANDSCAPE 334
16.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 334
17 SWOT ANALYSIS 335
18 COMPANY PROFILE 336
18.1 GILEAD SCIENCES, INC. (2022) 336
18.1.1 COMPANY SNAPSHOT 336
18.1.2 REVENUE ANALYSIS 336
18.1.3 COMPANY SHARE ANALYSIS 337
18.1.4 PRODUCT PORTFOLIO 337
18.1.5 RECENT DEVELOPMENT 337
18.2 PFIZER INC. (2022) 338
18.2.1 COMPANY SNAPSHOT 338
18.2.2 REVENUE ANALYSIS 338
18.2.3 COMPANY SHARE ANALYSIS 339
18.2.4 PRODUCT PORTFOLIO 339
18.2.5 RECENT DEVELOPMENTS 339
18.3 SIGA TECHNOLOGIES (2022) 340
18.3.1 COMPANY SNAPSHOT 340
18.3.2 REVENUE ANALYSIS 340
18.3.3 COMPANY SHARE ANALYSIS 341
18.3.4 PRODUCT PORTFOLIO 341
18.3.5 RECENT DEVELOPMENT 341
18.4 GLAXOSMITHKLINE PLC 342
18.4.1 COMPANY SNAPSHOT 342
18.4.2 REVENUE ANALYSIS 342
18.4.3 COMPANY SHARE ANALYSIS 343
18.4.4 PRODUCT PORTFOLIO 343
18.4.5 RECENT DEVELOPMENT 343
18.5 F. HOFFMANN-LA ROCHE LTD. (2022) 344
18.5.1 COMPANY SNAPSHOT 344
18.5.2 REVENUE ANALYSIS 344
18.5.3 COMPANY SHARE ANALYSIS 345
18.5.4 PRODUCT PORTFOLIO 345
18.5.5 RECENT DEVELOPMENT 345
18.6 ABBVIE INC 346
18.6.1 COMPANY SNAPSHOT 346
18.6.2 REVENUE ANALYSIS 346
18.6.3 PRODUCT PORTFOLIO 347
18.6.4 RECENT DEVELOPMENT 347
18.7 AUROBINDO PHARMA (2022) 348
18.7.1 COMPANY SNAPSHOT 348
18.7.2 REVENUE ANALYSIS 348
18.7.3 PRODUCT PORTFOLIO 349
18.7.4 RECENT DEVELOPMENT 349
18.8 AVET PHARMACEUTICALS INC 350
18.8.1 COMPANY SNAPSHOT 350
18.8.2 PRODUCT PORTFOLIO 350
18.8.3 RECENT DEVELOPMENT 350
18.9 BRISTOLL MYERS SQUIBB (2022) 351
18.9.1 COMPANY SNAPSHOT 351
18.9.2 REVENUE ANALYSIS 351
18.9.3 PRODUCT PORTFOLIO 352
18.9.4 RECENT DEVELOPMENT 352
18.10 BIOCRYST PHARMACEUTICALS, INC. (2022) 353
18.10.1 COMPANY SNAPSHOT 353
18.10.2 REVENUE ANALYSIS 353
18.10.3 PRODUCT PORTFOLIO 354
18.10.4 RECENT DEVELOPMENT 354
18.11 CIPLA INC. (2022) 355
18.11.1 COMPANY SNAPSHOT 355
18.11.2 REVENUE ANALYSIS 355
18.11.3 PRODUCT PORTFOLIO 356
18.11.4 RECENT DEVELOPMENT 356
18.12 DR. REDDY’S LABORATORIES LTD. (2022) 357
18.12.1 COMPANY SNAPSHOT 357
18.12.2 REVENUE ANALYSIS 357
18.12.3 PRODUCT PORTFOLIO 358
18.12.4 RECENT DEVELOPMENTS 358
18.13 EMERGENT (2022) 359
18.13.1 COMPANY SNAPSHOT 359
18.13.2 REVENUE ANALYSIS 359
18.13.3 PRODUCT PORTFOLIO 360
18.13.4 RECENT DEVELOPMENT 360
18.14 HETERO 361
18.14.1 COMPANY SNAPSHOT 361
18.14.2 PRODUCT PORTFOLIO 361
18.14.3 RECENT DEVELOPMENT 361
18.15 JOHNSON & JOHNSON PRIVATE LIMITED (2022) 362
18.15.1 COMPANY SNAPSHOT 362
18.15.2 REVENUE ANALYSIS 362
18.15.3 PRODUCT PORTFOLIO 363
18.15.4 RECENT DEVELOPMENT 363
18.16 MACLEODS PHARMACEUTICALS LTD 364
18.16.1 COMPANY SNAPSHOT 364
18.16.2 PRODUCT PORTFOLIO 364
18.16.3 RECENT DEVELOPMENT 364
18.17 MERCK & CO., INC, (2022) 365
18.17.1 COMPANY SNAPSHOT 365
18.17.2 REVENUE ANALYSIS 365
18.17.3 PRODUCT PORTFOLIO 366
18.17.4 RECENT DEVELOPMENT 366
18.18 MYLAN N.V (SUBSIDIARY OF VIATRIS) (2022) 367
18.18.1 COMPANY SNAPSHOT 367
18.18.2 REVENUE ANALYSIS 367
18.18.3 PRODUCT PORTFOLIO 368
18.18.4 RECENT DEVELOPMENT 368
18.19 NAVINTA LLC 369
18.19.1 COMPANY SNAPSHOT 369
18.19.2 PRODUCT PORTFOLIO 369
18.19.3 RECENT DEVELOPMENT 369
18.20 SUN PHARMACEUTICAL INDUSTRIES LTD. (2022) 370
18.20.1 COMPANY SNAPSHOT 370
18.20.2 REVENUE ANALYSIS 370
18.20.3 PRODUCT PORTFOLIO 371
18.20.4 RECENT DEVELOPMENT 371
18.21 TEVA PHARMACEUTICAL INDUSTRIES LTD. (2022) 372
18.21.1 COMPANY SNAPSHOT 372
18.21.2 REVENUE ANALYSIS 372
18.21.3 PRODUCT PORTFOLIO 373
18.21.4 RECENT DEVELOPMENT 373
18.22 ZYDUS PHARMACEUTICALS, INC. (2022) 374
18.22.1 COMPANY SNAPSHOT 374
18.22.2 REVENUE ANALYSIS 374
18.22.3 PRODUCT PORTFOLIO 375
18.22.4 RECENT DEVELOPMENTS 375
19 QUESTIONNAIRE 376
20 RELATED REPORTS 379